MAZE – maze therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
Maze Therapeutics (MAZE) was upgraded by Wall Street Zen from "sell"
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bachrodt Amy
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bernstein Harold
Form 4 Maze Therapeutics, Inc. For: Mar 30 Filed by: Dandekar Atul
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Paradigm Biocapital Advisors LP
Form 4 Maze Therapeutics, Inc. For: Mar 27 Filed by: Kumar Neil
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.